Prevalence of ROP severities in a multinational cohort of infants treated for ROP – data from the European ROP registry (EU-ROP)

#4913

Pfeil JM[1], Kara C[2], Uzun A[3], Oscar A[4], Ozdek S[5], Aisenbrey S[6], Breuss H[7], Barth T[8], Hufendiek K[9], Glitz B[10], Kakkassery V[11], Guthoff R[12], Motloch K[13], Katsan S[14], Caputo G[15], Stahl A[1] for the EU-ROP registry study group

Departments of ophthalmology at: [1]University medicine Greifswald, Germany; [2]Ankara Etlik Zubeyde Hanim Kadin Hastaliklari Egitim ve AraştirmaHastanesi, Turkey; [3]Ordu Universitesi, Turkey; [4]Universitetska mnogoprofilna bolnica za aktivno lecenie Aleksandrovska EAD, Sofia, Bulgaria; [5]Gazi Universitesi, Ankara, Turkey; [6]Vivantes Klinikum Neukölln, Berlin, Germany; [7]HELIOS Klinikum Berlin-Buch, Germany; [8]University medicine Regensburg, Germany; [9]Medizinische Hochschule Hannover, Germany; [10]Westfalische Wilhelms-Universitat Munster, Germany; [11]University Lubeck, Germany; [12]Heinrich-Heine-University Dusseldorf, Germany; [13]Paracelsus Medizinische Privatuniversitat, Salzburg, Austria; [14]Odes'kij nacional'nij universitet imeni I I Mecnikova, Odesa, Ukraine; [15]Hopital Rothschild, Paris, France

PURPOSE

In 2021, the third iteration of the International Classification of Retinopathy Of Prematurity (ICROP3) was published[1]. We investigated the **prevalence of ROP severities** in the recently established **European ROP registry (EU-ROP)**, which collects **real-life data** of infants **treated for ROP** in Europe.

CONCLUSION

This first analysis from the EU-ROP registry gives an **overview of ROP characteristics** present in a **real-world cohort of treatment-requiring ROP in Europe**. Additional analyses will follow to investigate treatment approaches, complications and outcomes.
See the project website **www.eu-rop.org** for further information.

RESULTS





*including two infants with bilateral treatment 23 and 92 days apart

Baseline characteristics	
Total N (infants // eyes)	203 // 393
Birth weight [median in g] (range) (N=202)	727 (250-2.470)
Gestational age at birth [median in weeks] (range) (N=199)	25.9 (22-34)
Female [n, children] (%) (N=202)	96 (47.5)
Multiples [n, children] (%) (N=202)	46 (22.8)





METHODS

First consecutive 203 infants with treatment warranted ROP from 30 centers located in 8 European countries were analyzed for demographics and ROP parameters at time of treatment.



Descriptive statistics to analyze:

- birthweight
- gestational age
- gender
- plurality
- stage of ROP
- zone
- plus disease

at time of initial ROP treatment

Financial disclosures: The EU-ROP registry is financed by extramural grants from the University Medicine Greifswald, solicited through the EU-ROP principal investigator from Novartis Pharma AG and Bayer AG. Companies supporting the registry do not have any influence on the content or the design of the registry.
KC, UA, OA, BH, HK, GB, GR, MK, KS, CG: None; **PJM:** Novartis (R); **OS:** Roche (C), Novartis (C), Bayer (C), Allergan (C); **AS:** Bayer (C), Novartis (C); **BT:** Bayer (R), Novartis (R), Bausch & Lomb (R); **KV:** Novartis (R); **SA:** Novartis (R, F), Bayer (R, F), Roche (R), Alcon (R), Speaker of the Board of Retina.net e.V. Germany and Member of the Board of the German Retina Society (S).

[1]Chiang MF, Quinn GE, Fielder AR, et al. (2021): International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology S0161642021004164.

www.eu-rop.org
Johanna.Pfeil@med.uni-greifswald.de